Search
Type
Audience
Category
Issue
Last updated
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 15 of 15 items.
Authorization of Casirivimab and Imdevimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
… Sale and Advertising of Drugs for Use in Relation to COVID-19 . Casirivimab and imdevimab, to be administered together, … treatment of mild to moderate coronavirus disease 2019 (COVID-19), confirmed by direct SARS-CoV-2 viral testing, in …
AlertHealth professional risk communication | 2021-07-30
Archived – Medication Errors Involving Reminyl and Amaryl – Janssen-Ortho Inc. and Aventis Pharma Inc.
… Images This is duplicated text of a letter from Janssen-Ortho Inc. & Aventis Pharma Inc. Contact the company … Care Professional: Please be aware of the following: Janssen-Ortho Inc. and Aventis Pharma Inc. (collectively, … Directorate at the following addresses: Janssen-Ortho Inc. 19 Green Belt Drive Toronto, OntarioM3C 1L9 Call toll-free at …
AlertHealth professional risk communication | 2004-12-21
Archived – Medication Errors Involving Reminyl and Amaryl –Janssen-Ortho Inc. and Aventis Pharma Inc.
… Images This is duplicated text of a letter from Janssen-Ortho Inc. & Aventis Pharma Inc. Contact the company … ® Dear Pharmacist: Please be aware of the following: Janssen-Ortho Inc. and Aventis Pharma Inc. (collectively, … Directorate at the following addresses: Janssen-Ortho Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 Call toll-free …
AlertHealth professional risk communication | 2004-12-21
Archived - Drug Release Information for the EVRA Transdermal Contraceptive System - For the Public
… Starting date: March 19, 2009 Posting date: March 19, 2009 Type of communication: … RA-19000741 This is duplicated text of a letter from Janssen-Ortho Inc. Contact the company for a copy of any … Footnote * Birth Control Patch Average Daily Release Rate Janssen-Ortho Inc., in cooperation with Health Canada, is …
AlertHealth professional risk communication | 2009-03-19
Archived – New Safety Information Regarding Intelence (etravirine) and Severe Skin and Hypersensitivity Reactions – For the Public
… Starting date: October 19, 2009 Posting date: October 19, 2009 Type of … is duplicated text of a letter from Tibotec, a division of Janssen-Ortho Inc . Contact the company for a copy of any … Severe Skin and Allergic Reactions Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in collaboration with Health …
AlertHealth professional risk communication | 2009-10-19
Risperdal Consta (risperidone powder for injectable prolonged-release suspension) – Needle Detachments Associated with the Needle Assembly Used for Gluteal Injection
… Images This is duplicated text of a letter from Janssen-Ortho Inc. Contact the company for a copy of any … powder for Injectable Prolonged-Release Suspension Janssen-Ortho, in cooperation with Health Canada, would like … Janssen-Ortho Inc. Medical Information Department 19 Green Belt Drive Toronto, Ontario M3C 1L9 Telephone: …
AlertHealth professional risk communication | 2010-05-25
Archived - PREPULSID (cisapride)
… effective August 7, 2000. PREPULSID, marketed by Janssen-Ortho Inc., is a prescription drug indicated for the … outweigh the risk of serious cardiac adverse events. Janssen-Ortho Inc. has indicated to Health Canada that it … The Special Access Programme is prepared to authorize Janssen- Ortho to release PREPULSID for these patients. …
AlertHealth professional risk communication | 2000-05-30
Archived – Important Drug Safety Information: Risperdal (Risperidone) and Cerebrovascular Adverse Events in Placebo-Controlled Dementia Trials – Janssen-Ortho Inc.
… RA-17000390 This is duplicated text of a letter from Janssen-Ortho Inc. Contact the company for a copy of any … Dementia Trials Dear Healthcare Professional: Janssen-Ortho Inc., following discussions with Health Canada, … USA-63 1% (5/462) 1% (2/163) BEL-14 0% (0/20) 0% (0/19) Total 4% (29/764) 2% (7/466) Four patients died in the …
AlertHealth professional risk communication | 2002-10-11
Archived – Medication Errors Involving REMINYL and AMARYL® – Janssen-Ortho Inc. and Aventis Pharma Inc.
… RA-19000210 This is duplicated text of a letter from Janssen-Ortho Inc. and Aventis Pharma Inc. Contact the … and AMARYL ® (glimepiride). Toronto, December 21, 2004 - Janssen-Ortho Inc. and Aventis Pharma Inc., (collectively, … Canada at the following addresses: Janssen-Ortho Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 Or call toll …
AlertHealth professional risk communication | 2004-12-21
Archived - Association of PREZISTA (darunavir) with hepatotoxicity
… RA-19000676 This is duplicated text of a letter from Janssen-Ortho Inc . Contact the company for a copy of any … and serious liver side effects Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in cooperation with Health … a division of Janssen-Ortho Inc. Drug Safety Department 19 Green Belt Drive Toronto, ON M3C 1L9 Tel: 800-567-3331 or …
AlertHealth professional risk communication | 2008-05-15
Archived – Updated Safety Information Announced in Canada for Patients Taking TOPAMAX (Topiramate) Regarding Higher than Normal Blood Acid Levels – Janssen-Ortho Inc. – For the Public
… RA-19000220 This is duplicated text of a letter from Janssen-Ortho Inc. Contact the company for a copy of any … than Normal Blood Acid Levels Toronto, January 20, 2004 - Janssen-Ortho, following discussions with Health Canada, is … ensure that they are aware of this new safety information. Janssen-Ortho is working with Health Canada to update the …
AlertHealth professional risk communication | 2004-01-26
Archived - Evra (norelgestromin and ethinyl estradiol) Transdermal System
… RA-170001355 This is duplicated text of a letter from Janssen-Ortho . Contact the company for a copy of any … Professional, Following discussions with Health Canada, Janssen-Ortho Inc. would like to update you on important new … Directorate at the following addresses: Janssen-Ortho Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 Or call toll …
AlertHealth professional risk communication | 2006-11-23
New Safety Information Regarding Intelence (etravirine) and Severe Skin and Hypersensitivity Reactions - For Health Professionals
… Starting date: October 15, 2009 Posting date: October 19, 2009 Type of communication: Dear Healthcare Professional … is duplicated text of a letter from Tibotec, a division of Janssen-Ortho Inc. Contact the company for a copy of any … Dear Health Care Professional, Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in collaboration with Health …
AlertHealth professional risk communication | 2009-10-19
Association of Prezista (darunavir) with hepatotoxicity - For Health Professionals
… RA-170001865 This is duplicated text of a letter from Janssen-Ortho Inc. Contact the company for a copy of any … * (darunavir) and hepatotoxicity Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in cooperation with Health … a division of Janssen-Ortho Inc. Drug Safety Department 19 Green Belt Drive Toronto, ON M3C 1L9 Tel: 800-567-3331 or …
AlertHealth professional risk communication | 2008-05-15
Certain Injectable and Inhalational Sterile Drugs Imported from Ben Venue Laboratories Inc. - Potential Supply Shortage - Notice to Hospitals
… 1-800-267-1088 CAELYX (DOXORUBICIN HYDROCHLORIDE) 02238389 Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 Phone / tél : … (BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)) 02262452 Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 …
AlertHealth professional risk communication | 2011-08-18